It depends on the standard you follow. As of September 2026, Starling Oncology, Inc. (STLN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.13% / 30% · (Cash+Inv) / Mkt Cap (36m) 0.57% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.13% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.57% / 33% · Receivables / Mkt Cap (36m) 0.94% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.13% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.57% / 33.33% · Receivables / Mkt Cap (24m) 0.94% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 44.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 20.3% / 33.33% · Receivables / Avg Assets (4Q) 35.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 38.6% / 33.33% · (Cash+ST Inv) / Total Assets 19.6% / 33.33% · (Cash+Recv) / Total Assets 52.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Starling Oncology, Inc. (STLN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Starling Oncology, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Starling Oncology, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Starling Oncology, Inc. (NASDAQ: STLN) is a Healthcare company (Medical - Care Facilities) with a market capitalization of $347M. The Maz Rating grades it against the other companies in its sector.
Starling Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.40, Starling Oncology, Inc. trades at 0.6x sales. Over the last twelve months it generated about $617M of revenue and a net loss of $29M. It runs a gross margin of 16.5%, an operating margin of -3.3% and a net margin of -5.7%. It shows return on equity of 150.8%, return on invested capital of -28.3% and a free cash flow yield of 5.4%. On the balance sheet: a debt-to-equity ratio of -2.62 and a current ratio of 1.11. Over the past 52 weeks the share price ranged from $2.32 to $7.13, with a beta of 0.42.
Starling Oncology, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.